Literature DB >> 1732979

Recurrent rectal cancer and scar: differentiation with PET and MR imaging.

K Ito1, T Kato, M Tadokoro, T Ishiguchi, M Oshima, T Ishigaki, S Sakuma.   

Abstract

The value of positron emission tomography (PET) and magnetic resonance (MR) imaging in differentiating recurrent rectal cancer and scar was investigated. PET with fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) and MR imaging were performed in 15 patients with suspected recurrence. FDG accumulation in the mass was measured by means of the differential absorption ratio (DAR). All 11 patients with confirmed recurrent rectal cancer had increased accumulation of FDG in the mass (DAR = 4.73 +/- 2.28). Low FDG accumulation in the mass (DAR = 0.97 +/- 0.15) was noted in the remaining four patients, in whom the presence of a scar was proved by means of follow-up observation with or without biopsy. On the MR images, the recurrent tumor could be differentiated from scar in all but one case. The lesion-muscle signal intensity ratios on the T2-weighted images for the recurrent tumor and scar were 2.18 +/- 0.55 and 0.89 +/- 0.30, respectively. PET and MR imaging complement each other in the differential diagnosis between recurrent rectal cancer and scar. PET may also permit the evaluation of the effect of therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732979     DOI: 10.1148/radiology.182.2.1732979

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

Review 1.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

2.  Recurrent malignant glioma: detection with 131I labeled monoclonal antibody G-22, positron emission tomography and magnetic resonance imaging.

Authors:  M Oshima; J Yoshida; T Wakabayashi; K Ito; M Tadokoro; T Kato; S Sakuma
Journal:  Ann Nucl Med       Date:  1993-05       Impact factor: 2.668

3.  Effects of a proton pump inhibitor on the physiological accumulation of fluoro-2-deoxy-D-glucose (FDG) in FDG-positron emission tomography.

Authors:  Yasushi Domeki; Erena Yamazaki; Akira Matsuura; Kazuhiro Kitajima; Koji Murakami; Hiroyuki Kato
Journal:  Surg Today       Date:  2012-07-24       Impact factor: 2.549

4.  The role of positron emission tomography in colorectal carcinoma.

Authors:  Oussama M Nachar
Journal:  Ochsner J       Date:  2002

5.  Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity.

Authors:  K Ito; T Kato; T Ohta; M Tadokoro; T Yamada; M Ikeda; M Nishino; T Ishigaki; S Gambhir
Journal:  Eur J Nucl Med       Date:  1996-10

Review 6.  Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

Authors:  C S Brock; S R Meikle; P Price
Journal:  Eur J Nucl Med       Date:  1997-06

7.  FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences.

Authors:  Verena Plodeck; Nuh N Rahbari; Juergen Weitz; Christoph G Radosa; Michael Laniado; Ralf-Thorsten Hoffmann; Klaus Zöphel; Bettina Beuthien-Baumann; Joerg Kotzerke; Joerg van den Hoff; Ivan Platzek
Journal:  Eur Radiol       Date:  2018-07-06       Impact factor: 5.315

8.  Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer.

Authors:  B M Burt; J L Humm; D A Kooby; O D Squire; S Mastorides; S M Larson; Y Fong
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

9.  Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.

Authors:  T Kato; H Fukatsu; K Ito; M Tadokoro; T Ota; M Ikeda; T Isomura; S Ito; M Nishino; T Ishigaki
Journal:  Eur J Nucl Med       Date:  1995-01

10.  Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.

Authors:  Meltem Caglar; Can Yener; Erdem Karabulut
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-09-12       Impact factor: 2.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.